Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin to train over...

    Lupin to train over 1,000 graduates for pharma industry

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-09-07T10:15:19+05:30  |  Updated On 7 Sept 2018 10:15 AM IST
    Lupin to train over 1,000 graduates for pharma industry

    New Delhi: Pharmaceutical giant, Lupin Limited expects to train more than 1,000 undergraduates into pharma professionals by the year 2020 under its Learn and Earn Initiative, a senior company official said.


    Lupin has launched its 'Learn and Earn' initiative in which candidate who has passed Standard 12 in the science stream with a minimum of 50 per cent marks but are facing financial constraints are taken for three-year-long course during which they are paid stipend and provided all the facilities.


    "Since 2011 Lupin has helped to create a total of 560 graduates with 181 students passing out this year (2018)," C Srinivasalu, senior vice president (HR) Lupin told reporters in Goa Thursday.


    "We expect to graduate more than 1,000 students by 2020 adding to the manpower resource of the pharmaceutical sector," Srinivasalu said adding that "most of these would be absorbed by Lupin."


    The company has initiated the 'Learn and Earn Initiative' at its facilities in Goa, Tarapur (Maharashtra), Indore (MP), Aurangabad (Maharashtra) and Sikkim, he said.


    During the course period, the candidate undergoes five days on-the-job training with one day of the classroom session, Srinivasalu said.


    Further, the students have to compulsorily work with Lupin for two years, after completing their course before they have their options open to join any other pharmaceutical firm.


    Mumbai-headquartered Lupin has estimated that by the year 2020 they would be spending almost Rs 20 crore on this programme. This program will bridge the manpower requirement of the pharmaceutical sector in a big way," he said.


    Addressing media, Yashwant Mahadik, president, global human resource, Lupin. said the program was conceptualized in the year 2010 due an acute shortage of skilled manpower.


    "Historically, Lupin was recruiting 1,000 plus fresh graduates every year with no relevant job skill, and sensed that there was a need of job-ready graduates with appropriate technical and life skills," he said.


    Mahadik claimed that the main aim of this program was to "create a ready pool of talent in India to be part of the booming pharmaceutical sector."

    accute shortageC SrinivasalugraduatesLaunchLearn and EarnLupinpharma graduatesPharma Industrypharma professionalsPharmaceutical industrypharmaceutical sectorTrainingYashwant Mahadik
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok